LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects

Abstract

Objective:

A recently published study showed the safety and efficacy of LSD-assisted psychotherapy in patients with anxiety associated with life-threatening diseases. Participants of this study were included in a prospective follow-up.

Method:

12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview. A Qualitative Content Analysis (QCA) was carried out on the interviews to elaborate about LSD effects and lasting psychological changes.

Results:

None of the participants reported lasting adverse reactions. The significant benefits as measured with the STAI were sustained over a 12-month period. In the QCA participants consistently reported insightful, cathartic and interpersonal experiences, accompanied by a reduction in anxiety (77.8%) and a rise in quality of life (66.7%). Evaluations of subjective experiences suggest facilitated access to emotions, confrontation of previously unknown anxieties, worries, resources and intense emotional peak experiences à la Maslow as major psychological working mechanisms. The experiences created led to a restructuring of the person’s emotional trust, situational understanding, habits and world view.

Conclusions:

LSD administered in a medically supervised psychotherapeutic setting can be safe and generate lasting benefits in patients with a life-threatening disease. Explanatory models for the therapeutic effects of LSD warrant further study.

Keywords

LSD psycho-oncology psycholytic therapy psychedelics hallucinogens

Get full access to this article

View all access options for this article.

References

Abramson

(ed) (1967) The Use of LSD in Psychotherapy and Alcoholism. New York: Bobbs-Merrill.

Adlam

Zaman

(2013) The role of BDNF and memory in major depressive disorder. Psychiatr Danub 2013(Suppl 2): S368–S369.

Behrendt

(2003) Hallucinations: Synchronisation of thalamocortical gamma oscillations underconstrained by sensory input. Conscious Cogn 12: 413–451.

Béïque

Imad

Mladenovic

. (2007) Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci U S A 104: 9870–9875.

Bullmore

Barnes

Bassett

. (2009) Generic aspects of complexity in brain imaging data and other biological systems. Neuroimage 47: 1125–1134.

Carhart-Harris

Friston

(2010) The default-mode, ego-functions and free-energy: A neurobiological account of Freudian ideas. Brain 133: 1265–1283.

Carhart-Harris

Erritzoe

Williams

. (2012a) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109: 2138–2143.

Carhart-Harris

Leech

Hellyer

. (2014) The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 8: 20.

Carhart-Harris

Leech

Williams

. (2012b) Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. Br J Psychiatry 200: 238–244.

10.

Cohen

(1960) Lysergic acid diethylamide: Side effects and complications. J Nerv Ment Dis 130: 30–40.

11.

Cyr

Landry

Di Paolo

(2000) Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology 23: 69–78.

12.

Diesch

(2014, in print) LSD: Rückkehr in die klinische Forschung. Solothurn: Nachtschatten.

13.

Eliade

(1975) Schamanismus und archaische Ekstasetechnik. Frankfurt: Suhrkamp.

14.

Fiorella

Rabin

Winter

(1995) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology (Berl) 121: 347–356.

15.

Gasser

(1996) Die Psycholytische Therapie in der Schweiz von 1988 – 1993. Schweiz Arch Neurol Psych 147: 59–65.

16.

Gasser

Holstein

Michel

. (2014) Safety and efficacy of LSD-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202: 513–520.

17.

Gouzoulis-Mayfrank

Schreckenberger

Sabri

. (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 20: 565–581.

18.

Griffiths

Johnson

Richards

. (2011) Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology 218: 649–665.

19.

Griffiths

Richards

McCann

. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187: 268–283.

20.

Grob

Danforth

Chopra

. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiat 68: 71–78.

21.

Grof

(1975) Realms of the Human Unconscious. New York, NY: Viking.

22.

Grof

(1980) LSD Psychotherapy. Pomona, CA: Hunter House.

23.

Grof

Goodman

Richards

. (1973) LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 8: 129–144.

24.

Gusnard

Akbudak

Shulman . (2007) Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function. Proc Natl Acad Sci U S A 98: 4259–64.

25.

Hagmann

Cammoun

Gigandet

. (2008) Mapping the structural core of human cerebral cortex. PLoS Biol 6: e159.

26.

Halberstadt

Geyer

(2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61: 364–381.

27.

Hariri

Drabant

Weinberger

(2006) Imaging genetics: Perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing. Biol Psychiatry 59: 888–897.

28.

Hintzen

Passie

(2010) The pharmacology of LSD. Oxford, UK: Oxford University Press.

29.

James

(1902) The varieties of religious experience. New York: Longmans Green.

30.

Jiang

Salton

(2013) The role of neurotrophins in major depressive disorder. Transl Neurosci 4: 46–58.

31.

Kast

(1967) Attenuation and anticipation: A therapeutic use of lysergic acid diethylamide. Psychiatric Quarterly 41: 646–657.

32.

Kirchner

(2010) LSD-supported psychotherapy: effects on daily life and longterm changes. MA Thesis, University of Zurich, Switzerland.

33.

Kurland

(1985) LSD in the supportive care of the terminally ill cancer patient. J Psychoactive Drugs 17: 279–290.

34.

Leuner

(1962) Die experimentelle Psychose. Berlin, Göttingen, Heildelberg: Springer.

35.

Leuner

(1967) Present state of psycholytic therapy and its possibilities. In: Abramson

(ed) The use of LSD in Psychotherapy and Alcoholism. New York et al.: Bobbs-Merrill, pp. 101–116.

36.

Leuner

(1981) Halluzinogene. Bern: Huber.

37.

McGlothlin

Cohen

McGlothlin

(1967) Long lasting effects of LSD on normals. Arch Gen Psychiat 17: 521–532.

38.

MacLean

Johnson

Griffiths

(2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25: 1453–1461.

39.

Malleson

(1971) Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Brit J Psychiatry 118: 229–230.

40.

MAPS (2007) LSD-assisted psychotherapy in persons suffering from anxiety associated with advanced-stage life threatening diseases. Study Report. Available at: http://maps.org/pdf/LDA1_FINAL_CSR_20Aug13.pdf (accessed 10 October 2014).

41.

Martín-Ruiz

Puig

Celada

. (2001) Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci 21: 9856–9866.

42.

Maslow

(1962) Lessons from the peak experience. J Humanistic Psychol 2: 9–18.

43.

Maslow

(1970) Religions, values, and peak experiences. New York: Viking.

44.

Maxwell

(2009) Designing a qualitative study. In: Bickman

Rog

(eds) Handbook of Applied Social Research Methods. Los Angeles, CA: Sage, pp. 214–253.

45.

Mayring

Glaeser-Zikuda

(eds) (2008) Die Praxis der qualitativen Inhaltsanalyse. Weinheim: Beltz.

46.

Meert

(1996) Serotonin mechanisms in antipsychotic treatment: evidence from drug discrimination studies. In: Kane

Moller

H-J

Awouters

(eds) Serotonin in antipsychotic treatment. New York: Marcel Dekker, pp. 109–130.

47.

Nichols

(2004) Hallucinogens. Pharmacol Ther 101: 131–181.

48.

Northoff

(2007) Psychopathology and pathophysiology of the self in depression – neuropsychiatric hypothesis. J Affect Disord 104: 1–14.

49.

Pahnke

(1969) The psychedelic mystical experience in the human encounter with death. Harvard Theol Rev 62: 1–21.

50.

Pahnke

Kurland

Unger

. (1970) The experimental use of psychedelic (LSD) psychotherapy. JAMA 212: 1856–1863.

51.

Passie

Halpern

Stichtenoth

. (2008) The pharmacology of lysergic acid diethylamide: A review. CNS Neurosci Ther 14: 295–314.

52.

Pizzagalli

(2011) Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 36: 183–206.

53.

Pierce

Peroutka

(1989) Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology 98: 118–122.

54.

Puig

Celada

Díaz-Mataix

. (2003) In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents. Cereb Cortex 13: 870–82.

55.

Raichle

(1998) The neural correlates of consciousness: An analysis of cognitive skill learning. Philos Trans R Soc Lond B Biol Sci 353: 1889–1901.

56.

Richards

Rhead

Dileo

. (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychoactive Drugs 9: 1–10.

57.

Savage

Fadiman

Mogar

. (1966) The effects of psychedelic (LSD) therapy on values, personality, and behavior. Int J Neuropsychiatry 2: 241–254.

58.

Schultes

Hofmann

(1980) Plants of the Gods: Origins of Hallucinogenic Use. London: Hutchinson.

59.

Schweizerische Krebsliga (2005) Schlussbericht Bestandesaufnahme psychosoziale Onkologie in der Schweiz. Bern: Krebsliga Schweiz.

60.

Sewell

Halpern

Pope

Jr. (2006) Response of cluster headache to psilocybin and LSD. Neurology 66: 1920–1922.

61.

Spielberger

Gorsuch

Lushene

(1970) Manual for the State Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press.

62.

Stuhrmann

Suslow

Dannlowski

(2011) Facial emotion processing in major depression: A systematic review of neuroimaging findings. Biol Mood Anxiety Disord 1: 10.

63.

Terrill James (1962) The nature of the LSD experience. J Nerv Ment Dis 135: 425–29.

64.

Unger

(1963) Mescaline, LSD, psilocybin, and personality change. Psychiatry 26: 111–125.

65.

Vaidya

Marek

Aghajanian

. (1997) 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 17: 2785–2795.

66.

Vázquez-Borsetti

Cortés

Artigas

(2009) Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors. Cereb Cortex 19: 1678–1686.

67.

Vollenweider

Geyer

(2001) A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Res Bull 56: 495–507.

68.

Vollenweider

Kometer

(2010) The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci 11: 642–651.

69.

Vollenweider

Leenders

Scharfetter

. (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16: 357–372.

70.

Vollenweider

Vontobel

Hell

. (1999) 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man – a PET study with [11C]raclopride. Neuropsychopharmacology 20: 424–433.

71.

Vollenweider

Vollenweider-Scherpenhuyzen

Bäbler

. (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897–3902.

72.

Weiss

(1995) Learning from Strangers: The Art and Method of Qualitative Interview Studies. New York, NY: Free Press.

73.

Winter

Eckler

Rabin

(2004) Serotonergic/glutamatergic interactions: The effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology (Berl) 172: 233–240.